By Chad D. Knights PhD, Richard G. Pestell MBBS, MD, PhD, FRACP (auth.), Howard L. Kaufman, Scott Wadler, Karen Antman (eds.)
In Molecular concentrating on in Oncology, authors current an outline of the improvement of particular cures for the therapy of melanoma with an emphasis on medical program. the quantity covers the complexity of the speedily constructing region of special cures for the remedy of sufferers with melanoma and is established in a fashion so readers could commence with chapters that the majority curiosity them and paintings throughout the remainder of the chapters within the order in their choice.
The quantity is split into 5 sections that disguise an important components of drug improvement. the 1st part specializes in techniques utilizing precise cures to inhibit phone development. the second one part describes how clinicians are comparing exact cures in particular organ structures. The 3rd part illustrates how quite a few sessions of pharmacologic and immunologic brokers are built for person molecular objectives. The fourth part information new medicinal drugs that experience novel mechanisms of motion. the ultimate part appears to the way forward for designated therapeutics and contains chapters on acceptable sufferer choice, use of mix remedy, facing tumor phone resistance, and extra. accomplished and state-of-the-art, Molecular concentrating on in Oncology is a vital reference for these operating within the field.
Read or Download Molecular Targeting in Oncology PDF
Similar oncology books
Energy Balance and Gastrointestinal Cancer
The gastrointestinal tune offers one of many detailed platforms the place a number of malignancies, together with adenocarcinoma of the pancreas, esophagus and colon are every one linked to weight problems. This detailed organization is roofed during this quantity of strength stability and melanoma from the epidemiologic, biologic and capability etiologic standpoint.
Brain Metastases from Primary Tumors. Epidemiology, Biology, and Therapy
With an annual price of greater than 12 million worldwide diagnoses and seven. 6 million deaths, the societal and monetary burden of melanoma can't be overstated. mind metastases are the most typical malignant tumors of the primary fearful process, but their prevalence seems to be expanding even with the development of melanoma treatments.
Branching Process Models of Cancer
This quantity develops effects on non-stop time branching strategies and applies them to check fee of tumor progress, extending vintage paintings at the Luria-Delbruck distribution. for this reason, the writer calculate the likelihood that mutations that confer resistance to therapy are current at detection and quantify the level of tumor heterogeneity.
- The MASCC Textbook of Cancer Supportive Care and Survivorship
- Drug Delivery in Oncology: From Basic Research to Cancer Therapy
- Breast Cancer: A Multidisciplinary Approach to Diagnosis and Managmenet (Current Multidisciplinary Oncology Series)
- Cancer du testicule
- Polynuclear Aromatic Compounds
- Genomics of Pattern Recognition Receptors: Applications in Oncology and Cardiovascular Diseases
Extra info for Molecular Targeting in Oncology
Example text
Cyclin D-cdk4 activity modulates the subnuclear localization and interaction of MEF2 with SRC-family coactivators during skeletal muscle differentiation. Genes Dev 2002; 16(14):1792–1805. 192. Morris L, Allen KE, La Thangue NB. Regulation of E2F transcription by cyclin E-Cdk2 kinase mediated through p300/CBP co-activators. Nat Cell Biol 2000; 2(4):232–239. 193. Adnane J, Shao Z, Robbins PD. Cyclin D1 associates with the TBP-associated factor TAF(II)250 to regulate Sp1-mediated transcription. Oncogene 1999; 18(1):239–247.
Mol Cell Biol 1997; 17(9): 5338–5347. 180. Lamb J, Ramaswamy S, Ford HL, Contreras B, Martinez RV, Kittrell FS et al. A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell 2003; 114(3):323–334. 181. Knudsen KE, Cavenee WK, Arden KC. D-type cyclins complex with the androgen receptor and inhibit its transcriptional transactivation ability. Cancer Res 1999; 59(10):2297–2301. 182. Lin HM, Zhao L, Cheng SY. Cyclin D1 is a ligand-independent co-repressor for thyroid hormone receptors.
Ratineau C, Petry MW, Mutoh H, Leiter AB. Cyclin D1 represses the basic helix-loop-helix transcription factor, BETA2/NeuroD. J Biol Chem 2002; 277(11):8847–8853. 187. Bienvenu F, Gascan H, Coqueret O. Cyclin D1 represses STAT3 activation through a Cdk4independent mechanism. J Biol Chem 2001; 276(20):16840–16847. 188. Skapek SX, Rhee J, Kim PS, Novitch BG, Lassar AB. Cyclin-mediated inhibition of muscle gene expression via a mechanism that is independent of pRb hyperphosphorylation. Mol Cell Biol 1996; 16(12):7043–7053.